From 2019 to 2023, around 34 percent of prostate cancer deaths in the United States were among men aged 75 to 84 years. During that period, the median age of death for prostate cancer was 79 years. This statistic shows the distribution of prostate cancer deaths in the United States between 2019 and 2023, by age.

From 2018 to 2022, around 34 percent of prostate cancer deaths in the United States were among men aged 75 to 84 years. During that period, the median age of death for prostate cancer was 79 years. This statistic shows the distribution of prostate cancer deaths in the United States between 2018 and 2022, by age.

Legacy unique identifier: P00630

From 2017 to 2021, around 42 percent of prostate cancer cases in the United States were among men aged 65 to 74 years. During that period, the median age at diagnosis for prostate cancer was 67 years. This statistic shows the distribution of prostate cancer cases in the United States in the period 2017-2021, by age.

ObjectiveUsing the latest cohort study of prostate cancer patients, explore the epidemiological trend and prognostic factors, and develop a new nomogram to predict the specific survival rate of prostate cancer patients.MethodsPatients with prostate cancer diagnosed from January 1, 1975 to December 31, 2019 in the Surveillance, Epidemiology, and End Results Program (SEER) database were extracted by SEER stat software for epidemiological trend analysis. General clinical information and follow-up data were also collected from 105 135 patients with pathologically diagnosed prostate cancer from January 1, 2010 to December 1, 2019. The factors affecting patient-specific survival were analyzed by Cox regression, and the factors with the greatest influence on specific survival were selected by stepwise regression method, and nomogram was constructed. The model was evaluated by calibration plots, ROC curves, Decision Curve Analysis and C-index.ResultsThere was no significant change in the age-adjusted incidence of prostate cancer from 1975 to 2019, with an average annual percentage change (AAPC) of 0.45 (95% CI:-0.87~1.80). Among the tumor grade, the most significant increase in the incidence of G2 prostate cancer was observed, with an AAPC of 2.99 (95% CI:1.47~4.54); the most significant decrease in the incidence of G4 prostate cancer was observed, with an AAPC of -10.39 (95% CI:-13.86~-6.77). Among the different tumor stages, the most significant reduction in the incidence of localized prostate cancer was observed with an AAPC of -1.83 (95% CI:-2.76~-0.90). Among different races, the incidence of prostate cancer was significantly reduced in American Indian or Alaska Native and Asian or Pacific Islander, with an AAPC of -3.40 (95% CI:-3.97~-2.82) and -2.74 (95% CI:-4.14~-1.32), respectively. Among the different age groups, the incidence rate was significantly increased in 15-54 and 55-64 age groups with AAPC of 4.03 (95% CI:2.73~5.34) and 2.50 (95% CI:0.96~4.05), respectively, and significantly decreased in ≥85 age group with AAPC of -2.50 (95% CI:-3.43~-1.57). In addition, age, tumor stage, race, PSA and gleason score were found to be independent risk factors affecting prostate cancer patient-specific survival. Age, tumor stage, PSA and gleason score were most strongly associated with prostate cancer patient-specific survival by stepwise regression screening, and nomogram prediction model was constructed using these factors. The Concordance indexes are 0.845 (95% CI:0.818~0.872) and 0.835 (95% CI:0.798~0.872) for the training and validation sets, respectively, and the area under the ROC curves (AUC) at 3, 6, and 9 years was 0.7 or more for both the training and validation set samples. The calibration plots indicated a good agreement between the predicted and actual values of the model.ConclusionsAlthough there was no significant change in the overall incidence of prostate cancer in this study, significant changes occurred in the incidence of prostate cancer with different characteristics. In addition, the nomogram prediction model of prostate cancer-specific survival rate constructed based on four factors has a high reference value, which helps physicians to correctly assess the patient-specific survival rate and provides a reference basis for patient diagnosis and prognosis evaluation.

Legacy unique identifier: P00624

This dataset contains Cancer Incidence data for Prostate Cancer(All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for males segmented age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

The highest average age at cancer diagnosis among women in Russia was recorded for lip cancer, at over 76 years in 2023. Among men, prostate cancer had the highest mean age, at nearly 70 years. The earliest detection age for male patients concerned thyroid cancer and cervix cancer for female patients.

For 2023, it was estimated that there would be 3,200 new prostate cancer cases among those aged 50 to 59 years in Canada. This statistic displays the estimated number of new prostate cancer cases in Canada among males by age group in 2023.

Variables included in the best fitted models for different types of cancer mortality; main variables are denoted as age (a), year (t), gender (g), region (r), deprivation (d), average age-at-diagnosis (AAD), with corresponding interactions shown as, e.g., a:t.

From 2018 to 2022, around 43 percent of prostate cancer cases in the United States were among men aged 65 to 74 years. During that period, the median age at diagnosis for prostate cancer was 68 years. This statistic shows the distribution of prostate cancer cases in the United States in the period 2018-2022, by age.

ABSTRACT: Objective: To analyze cancer-specific mortality (CSM) and other-cause mortality (OCM) among patients with prostate cancer that initiated treatment in the Brazilian Unified Health System (SUS), between 2002 and 2010, in Brazil. Methods: Retrospective observational study that used the National Oncological Database, which was developed by record-linkage techniques used to integrate data from SUS Information Systems, namely: Outpatient (SIA-SUS), Hospital (SIH-SUS), and Mortality (SIM-SUS). Cancer-specific and other-cause survival probabilities were estimated by the time elapsed between the date of the first treatment until the patients’ deaths or the end of the study, from 2002 until 2015. The Fine-Gray model for competing risk was used to estimate factors associated with patients’ risk of death. Results: Of the 112,856 studied patients, the average age was 70.5 years, 21% died due to prostate cancer, and 25% due to other causes. Specific survival in 160 months was 75%, and other-cause survival was 67%. For CSM, the main factors associated with patients’ risk of death were: stage IV (AHR = 2.91; 95%CI 2.73 - 3.11), systemic treatment (AHR = 2.10; 95%CI 2.00 - 2.22), and combined surgery (AHR = 2.30, 95%CI 2.18 - 2.42). As for OCM, the main factors associated with patients’ risk of death were age and comorbidities. Conclusion: The analyzed patients with prostate cancer were older and died mainly from other causes, probably due to the presence of comorbidities associated with the tumor.

The highest average age at death among female cancer patients in Russia was recorded for those with a non-melanoma skin malignant neoplasm, at over 76 years in 2023. In men, prostate cancer displayed the highest mean age at death, at nearly 73 years. On average, male cancer patients in the country deceased earlier than their female counterparts.

BackgroundAmong prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. PC treatments may be associated with side effects, including second primary malignancies (SPM). There is limited information on the incidence of SPM among men with bone metastatic PC (mPC) and among men with bone metastatic castration-resistant PC (mCRPC). We estimated overall survival and the incidence of SPM in men with mPC and mCRPC.MethodsIn the Prostate Cancer data Base Sweden, the National Prostate Cancer Register was linked to other national health care registers, 15,953 men with mPC in 1999–2011 were identified. Further, 693 men with mCRPC were identified. Outcomes were evaluated using stratified incidence rates, Kaplan-Meier estimators and Cox models.ResultsThe mean age among men with mPC was 73.9 years and in men with mCRPC 70.0 years. The median respective survivals were 1.5 (13,965 deaths) and 1.14 years (599 deaths), and average times since PC diagnosis 1.8 and 4.7 years. We observed 2,669 SPMs in men with mPC and 100 SPMs in men with mCRPC. The incidence rate of SPM per 1,000 person-years was 81.8 (78.8–85.0) for mPC and 115.6 (95.1–140.7) for mCRPC. High age, prior neoplasms, urinary tract infection, congestive heart failure, diabetes and renal disease were most strongly associated with increased mortality risk. Prior neoplasms and prior use of antineoplastic agents were most strongly associated with increased SPM risk. Several factors associated with increased mortality and SPM risks were more prevalent in the mCRPC cohort.ConclusionsOur results on mortality for men with mPC and mCRPC are in line with previous studies from the same time period. Investigation of factors associated with mortality and SPM in men with mPC and mCRPC can help to further understand these outcomes in the era prior to several new treatments have come available.

ObjectiveSocial determinants of health (SDoH) are increasingly recognized as key factors in addressing health inequities. This study aimed to explore the association between SDoH and risk of prostate cancer (PCa).MethodsWe analyzed data from the National Health and Nutrition Examination Survey 2003–2010. PCa diagnosis was based on self-reported questionnaires, while highly-probable PCa was assessed using prostate-specific antigen levels. Multivariate logistic regression, restricted cubic spline, and subgroup analysis were performed. Three models were employed: the crude model (unadjusted), model 1 (adjusted for age and race/ethnicity), and model 2 (further adjusted for body mass index, alcohol consumption, and smoking status).ResultsThe median age of 5,633 participants was 54 years. A negative association was found between the SDoH score and PCa prevalence (OR = 0.868, 95% CI: 0.786–0.959, p = 0.006). Specifically, a family income-to-poverty ratio < 3 (OR = 0.69, 95% CI: 0.499–0.954, p = 0.029) and lack of healthcare access or reliance on emergency rooms (OR = 0.429, 95% CI: 0.218–0.842, p = 0.017) were independently associated with lower PCa prevalence. In model 2, no significant association was found between SDoH and highly probable PCa. A linear association between SDoH and PCa prevalence was observed. A consistently negative association was noted among participants aged ≥ 60 years, Non-Hispanic Black, Non-Hispanic White, and non-obese individuals.ConclusionsThe negative association between SDoH and PCa prevalence is likely attributable to inadequate screening and underreporting, rather than any protective effects. Unfavorable SDoH is not a risk factor for the onset of PCa. This study underscores the importance of addressing disparities in healthcare access and improving equity in PCa screening.

Prostate Specific Antigen (PSA) Testing Market Outlook

The global market size for Prostate Specific Antigen (PSA) testing was valued at approximately USD 3.8 billion in 2023 and is anticipated to reach USD 6.4 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period. The growth of the PSA testing market is driven by several factors, including the increasing prevalence of prostate cancer, advancements in testing technologies, and heightened awareness regarding early diagnosis and treatment. Prostate cancer is one of the most commonly diagnosed cancers in men worldwide, which underscores the necessity for efficient and reliable screening methods such as PSA testing.

The rising prevalence of prostate cancer is one of the primary growth factors contributing to the PSA testing market expansion. The aging global population is a significant driver, as prostate cancer risk increases with age. WHO estimates indicate a steady increase in the average lifespan, leading to a higher proportion of older individuals, which in turn propels the demand for PSA testing. Furthermore, enhanced patient awareness regarding prostate health and the importance of regular screenings have resulted in more men undergoing PSA tests. Early detection through PSA testing leads to timely intervention, significantly improving patient outcomes and survival rates, thus promoting market growth.

Technological advancements in PSA testing are another key growth factor. Innovations such as highly sensitive assays and improved analytical techniques have enhanced the accuracy and reliability of test results. These advancements have not only reduced the incidence of false positives and negatives but also allowed for more personalized and targeted screening strategies. In addition, research on genetic markers and integration with artificial intelligence (AI) is paving the way for next-generation PSA tests, which can provide more comprehensive assessments of prostate cancer risk. The ongoing development of such technologies is expected to further fuel market growth during the forecast period.

The increasing focus on preventive healthcare plays a crucial role in driving the PSA testing market. Governments and healthcare organizations worldwide are emphasizing the importance of early disease detection and prevention to reduce the burden of prostate cancer. Public health campaigns and screening programs have been instrumental in educating men about the risks of prostate cancer and encouraging regular PSA testing. Additionally, healthcare policies that support reimbursement for PSA tests have made screenings more accessible, particularly in developed regions. This supportive healthcare infrastructure has created a conducive environment for the growth of the PSA testing market.

From a regional perspective, North America currently holds the largest share of the PSA testing market, attributed to the well-established healthcare infrastructure, high awareness levels, and the presence of key market players. The region is expected to continue its dominance throughout the forecast period. Meanwhile, the Asia Pacific region is anticipated to witness the most rapid growth, driven by improving healthcare facilities, increasing awareness, and a growing incidence of prostate cancer. Emerging economies in Asia, such as India and China, offer lucrative opportunities due to their large patient populations and expanding healthcare investments. Europe and Latin America also present growth potential, supported by ongoing health system improvements and increasing screening rates.

Test Type Analysis

The PSA testing market is broadly segmented into Total PSA, Free PSA, and Complexed PSA tests. Total PSA testing holds the largest market share among these segments due to its long-standing application in routine prostate cancer screening and monitoring. Total PSA tests measure the overall level of prostate-specific antigen in the blood, providing a general indication of prostate health. The simplicity and widespread availability of Total PSA tests have contributed to their dominance in the market. However, the segment is evolving with ongoing advancements aimed at improving accuracy and reducing unnecessary biopsies, which can further bolster its market position.

Free PSA testing is gaining traction as a complementary diagnostic tool that enhances the specificity of prostate cancer screening. Free PSA tests measure the proportion of unbound PSA in the blood, differentiating between benign and malignant conditions. This test is particularly beneficial for patients with borderline Total PSA levels,

Prostate cancer incidence is increasing in younger men. We investigated whether men diagnosed with Gleason 7 (3+4) T2 prostate cancer at younger ages (≤ 45 years, young cohort) had different mRNA and miRNA expression profiles than men diagnosed at older ages (71–74 years, older cohort). We identified differentially expressed genes (DEGs) related to tumor-normal differences between the cohorts. Subsequent pathway analysis of DEGs revealed that the young cohort had significantly more pronounced inflammatory and immune responses to tumor development compared to the older cohort. Further supporting a role of inflammation-induced immune-suppression in the development of early-onset prostate cancer, we observed significant up-regulation of CTLA4 and IDO1/TDO2 pathways in tumors of the young cohort. Moreover, over-expression of CTLA4 and IDO1 was significantly associated with biochemical recurrence. Our results provide clues on the mechanisms of tumor development and point to potential biomarkers for early detection and treatment for prostate cancer in young men.

Years of life lost due to mortality from prostate cancer (ICD-10 C61). Years of life lost (YLL) is a measure of premature mortality. Its primary purpose is to compare the relative importance of different causes of premature death within a particular population and it can therefore be used by health planners to define priorities for the prevention of such deaths. It can also be used to compare the premature mortality experience of different populations for a particular cause of death. The concept of years of life lost is to estimate the length of time a person would have lived had they not died prematurely. By inherently including the age at which the death occurs, rather than just the fact of its occurrence, the calculation is an attempt to better quantify the burden, or impact, on society from the specified cause of mortality. Legacy unique identifier: P00245

The proportion of deaths from prostate cancer (ICD-10 C61) that occur at home. To improve palliative care and service planning for cancer patients in the terminal stages of life, allowing more of them the choice of dying at home. Legacy unique identifier: P00772

The first case of COVID-19 in Sweden was diagnosed in late January 2020, the first recommendations against the spread of the virus were released in mid-March, and the peak of the first wave of the pandemic was reached in March-June. The aim of this cross-sectional study was to assess the short-term effects of the first wave of the COVID-19 pandemic on prostate cancer (PCa) diagnosis, staging, and treatment. Data in the National Prostate Cancer Register (NPCR) of Sweden on newly diagnosed PCa cases and on the number of diagnostic and therapeutic procedures performed between 18 March 2020 and 2 June 2020 were compared with those in the corresponding time periods in 2017–2019, as reported until January 31 of the year after each study period. During the study period in 2020, 36% fewer PCa cases were registered in NPCR compared with the corresponding time period in previous years: 1458 cases in 2020 vs a mean of 2285 cases in 2017–2019. The decrease in new PCa registrations was more pronounced in men above age 75 years, down 51%, than in men aged 70–75, down 37%, and in men below age 70, down 28%. There was no decrease in the number of radical prostatectomies and number of radical radiotherapy courses increased by 32%. During the peak of the first phase of the COVID-19 pandemic, the number of men diagnosed with PCa in Sweden decreased by one third compared with previous years, whereas there was no decrease in the number of curative treatments.